Shares of Insmed, Inc. (NASDAQ:INSM) have been assigned an average recommendation of “Buy” from the ten analysts that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $36.71.

A number of equities research analysts recently weighed in on INSM shares. Zacks Investment Research upgraded shares of Insmed from a “hold” rating to a “buy” rating and set a $19.00 price objective on the stock in a research note on Wednesday, July 5th. HC Wainwright restated a “buy” rating on shares of Insmed in a research note on Wednesday, August 2nd. Stifel Nicolaus restated a “buy” rating and set a $43.00 price objective (up from $27.00) on shares of Insmed in a research note on Wednesday, September 6th. ValuEngine upgraded shares of Insmed from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Finally, BidaskClub upgraded shares of Insmed from a “sell” rating to a “hold” rating in a research note on Friday, June 23rd.

COPYRIGHT VIOLATION WARNING: This news story was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States & international copyright and trademark law. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2017/09/25/insmed-inc-insm-receives-36-71-consensus-price-target-from-brokerages.html.

Insmed (NASDAQ INSM) traded down 0.28% during trading on Wednesday, hitting $28.42. 911,567 shares of the stock were exchanged. The company’s market cap is $1.77 billion. Insmed has a one year low of $10.21 and a one year high of $31.39. The stock’s 50 day moving average is $17.85 and its 200-day moving average is $17.15.

Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.09). On average, equities research analysts expect that Insmed will post ($2.70) earnings per share for the current fiscal year.

In related news, Director Donald J. Hayden, Jr. sold 45,000 shares of Insmed stock in a transaction dated Thursday, September 7th. The stock was sold at an average price of $29.67, for a total transaction of $1,335,150.00. Following the transaction, the director now directly owns 71,131 shares of the company’s stock, valued at $2,110,456.77. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Melvin Md Sharoky sold 50,000 shares of Insmed stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $27.37, for a total value of $1,368,500.00. The disclosure for this sale can be found here. 5.10% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. The Manufacturers Life Insurance Company increased its stake in Insmed by 0.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 49,163 shares of the biopharmaceutical company’s stock worth $844,000 after purchasing an additional 197 shares in the last quarter. Legal & General Group Plc increased its stake in Insmed by 2.0% in the 2nd quarter. Legal & General Group Plc now owns 20,173 shares of the biopharmaceutical company’s stock worth $347,000 after purchasing an additional 390 shares in the last quarter. Parametric Portfolio Associates LLC increased its stake in Insmed by 11.2% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 16,035 shares of the biopharmaceutical company’s stock worth $275,000 after purchasing an additional 1,618 shares in the last quarter. TIAA CREF Investment Management LLC increased its stake in Insmed by 0.9% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 213,525 shares of the biopharmaceutical company’s stock worth $3,664,000 after purchasing an additional 1,857 shares in the last quarter. Finally, Voya Investment Management LLC increased its stake in Insmed by 9.3% in the 2nd quarter. Voya Investment Management LLC now owns 27,960 shares of the biopharmaceutical company’s stock worth $480,000 after purchasing an additional 2,389 shares in the last quarter. 73.08% of the stock is currently owned by hedge funds and other institutional investors.

About Insmed

Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC).

Analyst Recommendations for Insmed (NASDAQ:INSM)

Receive News & Stock Ratings for Insmed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed Inc. and related stocks with our FREE daily email newsletter.